Predictive factors for skeletal-related events in lung cancer

被引:1
作者
Villemain, A. [1 ]
Baptista, B. Ribeiro [2 ]
Paillot, N. [3 ]
Soudant, M. [4 ]
Menard, O. [2 ]
Martinet, Y. [5 ]
Tiotiu, A. [2 ]
机构
[1] Univ Paris VI, Grp Hosp Pitie Salpetriere, AP HP, Serv Oncol Med, 47-83 Blvd Hop, F-75651 Paris, France
[2] CHRU Nancy, Dept Pneumol, Rue Morvan, F-54500 Vandoeuvre Les Nancy, France
[3] Ctr Hosp & Reg CHR Metz Thionville, Serv Pneumol, 1 Allee Chateau, F-57085 Ars Laquenexy, France
[4] Univ Lorraine, CHRU Nancy, Epidemiol Clin, INSERM,CIC, F-54000 Nancy, France
[5] Univ Lorraine, Fac Med, F-54500 Vandoeuvre Les Nancy, France
关键词
Lung cancer; Bone metastasis; Skeletal-related events; Predictive factors; Calcemia; BONE METASTASES; ZOLEDRONIC ACID; SOLID TUMORS; MARKERS; COMPLICATIONS; TURNOVER; COST;
D O I
10.1016/j.rmr.2019.11.647
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction. - Skeletal-related events (SRE) are common in patients with bone metastatic lung cancer and have a negative impact on quality of life and survival. The objective of this study is to identify predictive factors for SRE occurrence among this population. Methods. - We conducted a 3-year retrospective study including 100 lung cancer patients with bone metastasis. Results. - Eighty-two patients presented at least one SRE (69.5% at baseline). The median occurrence for SRE was 4.5 months and severe bone pain was the most common SRE (56%). The alkaline phosphatase serum level > 120 IU/L (hazard ratio [sHR] = 2.8; 95% confidence interval (CI) [1.5-5.4]; P = 0.002) and calcemia > 2.6 mmol/L ([sHR] = 9.7; 95% CI [5.1-18.4]; P < 0.001) were identified as risk factors for SRE occurrence while the presence of an initial SRE was associated with a decrease of this risk ([sHR] = 0.2; 95% CI [0.1-0.4]; P < 0.001). Conclusion. - The elevated alkaline phosphatase serum level and hypercalcemia are risk factors for SRE occurrence in bone metastatic lung cancer patients and should be used as biomarkers to adapt current medical practice for these patients. (c) 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 25 条
  • [1] Usefulness of bone markers for detection of bone metastases in lung cancer patients
    Alatas, F
    Alatas, Ö
    Metintas, M
    Çolak, Ö
    Erginel, S
    Harmanci, E
    [J]. CLINICAL BIOCHEMISTRY, 2002, 35 (04) : 293 - 296
  • [2] Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis
    Bae, Hyun-Mi
    Lee, Se-Hoon
    Kim, Tae Min
    Kim, Dong-Wan
    Yang, Seok-Chul
    Wu, Hong Gyun
    Kim, Young Whan
    Heo, Dae Seog
    [J]. LUNG CANCER, 2012, 77 (03) : 572 - 577
  • [3] The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer
    Bayrak, Suna Bilgin
    Ceylan, Emel
    Serter, Mukadder
    Karadag, Fisun
    Demir, Ece
    Cildag, Orhan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (02) : 112 - 118
  • [4] Berruti A, 1999, CLIN CHEM, V45, P1240
  • [5] Bone matters in lung cancer
    Brodowicz, T.
    O'Byrne, K.
    Manegold, C.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (09) : 2215 - 2222
  • [6] Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
    Brown, JE
    Cook, RJ
    Major, P
    Lipton, A
    Saad, F
    Smith, M
    Lee, KA
    Zheng, M
    Hei, YJ
    Coleman, RE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 59 - 69
  • [7] Cetin K, 2014, LUNG CANC
  • [8] The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications
    Clezardin, Philippe
    [J]. BULLETIN DU CANCER, 2011, 98 (07) : 837 - 846
  • [9] Bone health in cancer patients: ESMO Clinical Practice Guidelines
    Coleman, R.
    Body, J. J.
    Aapro, M.
    Hadji, P.
    Herrstedt, J.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 : 124 - 137
  • [10] Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer
    da Silva, Gustavo Telles
    Bergmann, Anke
    Santos Thuler, Luiz Claudio
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 731 - 736